Patents by Inventor Johan Areberg

Johan Areberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating dementia and pharmaceutical compositions thereof
    Patent number: 10660878
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: May 26, 2020
    Assignee: H. LUNDBECK A/S
    Inventors: Ellen Schmidt, Johan Areberg
  • Dosage and Use of an A2A Antagonist
    Publication number: 20180125835
    Abstract: The present invention relates to specific dosages of an A2A antagonist for use as a medicament and in particular useful for the treatment of Parkinson Disease and Attention Deficit/Hyperactivity Disorder.
    Type: Application
    Filed: November 10, 2017
    Publication date: May 10, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Lone Frydelund Larsen, Johan Areberg, Nathalie Breysse, Gamini Chandrasena
  • METHODS OF TREATING DEMENTIA AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20180071254
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Application
    Filed: September 6, 2017
    Publication date: March 15, 2018
    Inventors: Ellen SCHMIDT, Johan AREBERG
  • Methods of treating dementia and pharmaceutical compositions thereof
    Patent number: 9789085
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: October 17, 2017
    Assignee: H. LUNDBECK A/S
    Inventors: Ellen Schmidt, Johan Areberg
  • Methods of treating Alzheimer's disease and pharmaceutical compositions thereof
    Patent number: 9687473
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 27, 2017
    Assignee: H. LUNDBECK A/S
    Inventors: Ellen Schmidt, Johan Areberg
  • Methods of treating Alzheimer's disease and pharmaceutical compositions thereof
    Patent number: 9642837
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: May 9, 2017
    Assignee: H. LUNDBECK A/S
    Inventors: Ellen Schmidt, Johan Areberg
  • METHODS OF TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20160354343
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 8, 2016
    Inventors: Ellen SCHMIDT, Johan AREBERG
  • METHODS OF TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20160256437
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Application
    Filed: March 30, 2016
    Publication date: September 8, 2016
    Inventors: Ellen SCHMIDT, Johan AREBERG
  • Methods of treating alzheimer's disease and pharmaceutical compositions thereof
    Patent number: 9375418
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: June 28, 2016
    Assignee: H. LUNDBECK A/S
    Inventors: Ellen Schmidt, Johan Areberg
  • Dosage and Use of an A2A Antagonist
    Publication number: 20160158211
    Abstract: The present invention relates to specific dosages of an A2A antagonist for use as a medicament and in particular useful for the treatment of Parkinson Disease and Attention Deficit/Hyperactivity Disorder.
    Type: Application
    Filed: December 1, 2015
    Publication date: June 9, 2016
    Applicant: H. Lundbeck A/S
    Inventors: Lone Frydelund Larsen, Johan Areberg, Nathalie Breysse, Gamini Chandrasena
  • METHODS OF TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20140073681
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-(2-(6-fluoro-1H-indol-3-yl)ethyl-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Application
    Filed: September 9, 2013
    Publication date: March 13, 2014
    Applicant: H. LUNDBECK A/S
    Inventors: Ellen Schmidt, Johan Areberg